Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)
Introduction
Anthracyclines are included in chemotherapy regimens to treat several different types of cancer and are extremely effective. However, it is recognised that a significant side effect is cardiotoxicity; anthracyclines can cause irreversible damage to cardiac cells and ultimately impaired cardiac function and heart failure, which may only be evident years after exposure. The PROACT trial will establish the effectiveness of the ACE inhibitor enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin’s lymphoma (NHL) receiving anthracycline-based chemotherapy.
M...
Source: BMJ Open - December 30, 2022 Category: General Medicine Authors: Maier, R. H., Plummer, C., Kasim, A. S., Akhter, N., Ogundimu, E., Maddox, J., Graham, J., Stewart, M., Wardley, A., Haney, S., Vahabi, S., Oxenham, H., Humphreys, A., Cresti, N., Verrill, M., Graham, R., Chang, L., Hancock, H. C., Austin, D. Tags: Open access, Cardiovascular medicine Source Type: research
Burden of and factors associated with poor quality antibiotic, antimalarial, antihypertensive and antidiabetic medicines in Malawi
by Francis Kachidza Chiumia, Happy Magwaza Nyirongo, Elizabeth Kampira, Adamson Sinjani Muula, Felix Khuluza
ObjectiveTo assess the prevalence and factors associated with substandard and falsified (SF) medicines among antibiotic, antimalarial, antihypertensive and antidiabetic medicines in Malawi. MethodsWe conducted a cross-sectional study in 23 public, faith-based and private health facilities in Zomba, Machinga and Nsanje districts. We analyzed oral medicine samples of commonly used medicines among antibiotics, antimalarial, antihypertensive and antidiabetics in accordance with Malawi Essential Medicines List and local ...
Source: PLoS One - December 27, 2022 Category: Biomedical Science Authors: Francis Kachidza Chiumia Source Type: research
Mathematical modeling of antihypertensive therapy
This study is a continuation of research on the modular agent-based model of the cardiovascular and renal systems (presented in the previously published article). In the current work, we included in the model equations simulating the response to antihypertensive therapies with different mechanisms of action. For this, we used the pharmacodynamic effects of the angiotensin II receptor blocker losartan, the calcium channel blocker amlodipine, the angiotensin-converting enzyme inhibitor enalapril, the direct renin inhibitor aliskiren, the thiazide diuretic hydrochlorothiazide, and the β-blocker bisoprolol. We fitted therapy ...
Source: Frontiers in Physiology - December 14, 2022 Category: Physiology Source Type: research
Identification of regulatory variants of carboxylesterase 1 (CES1): A proof ‐of‐concept study for the application of the Allele‐Specific Protein Expression (ASPE) assay in identifying cis‐acting regulatory genetic polymorphisms
This study suggests that the ASPE approach is a powerful tool for identifyingcis-regulatory variants. (Source: Proteomics)
Source: Proteomics - December 7, 2022 Category: Biochemistry Authors: Lucy Her,
Jian Shi,
Xinwen Wang,
Bing He,
Logan S. Smith,
Hui Jiang,
Hao ‐Jie Zhu Tags: RESEARCH ARTICLE Source Type: research
Author Correction: Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril
Eur Rev Med Pharmacol Sci. 2022 Nov;26(22):8204. doi: 10.26355/eurrev_202211_30347.NO ABSTRACTPMID:36459001 | DOI:10.26355/eurrev_202211_30347 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - December 2, 2022 Category: Drugs & Pharmacology Authors: N Ferri A Corsini R Pontremoli Source Type: research
Author Correction: Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril
Eur Rev Med Pharmacol Sci. 2022 Nov;26(22):8204. doi: 10.26355/eurrev_202211_30347.NO ABSTRACTPMID:36459001 | DOI:10.26355/eurrev_202211_30347 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - December 2, 2022 Category: Drugs & Pharmacology Authors: N Ferri A Corsini R Pontremoli Source Type: research
Author Correction: Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril
Eur Rev Med Pharmacol Sci. 2022 Nov;26(22):8204. doi: 10.26355/eurrev_202211_30347.NO ABSTRACTPMID:36459001 | DOI:10.26355/eurrev_202211_30347 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - December 2, 2022 Category: Drugs & Pharmacology Authors: N Ferri A Corsini R Pontremoli Source Type: research
Author Correction: Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril
Eur Rev Med Pharmacol Sci. 2022 Nov;26(22):8204. doi: 10.26355/eurrev_202211_30347.NO ABSTRACTPMID:36459001 | DOI:10.26355/eurrev_202211_30347 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - December 2, 2022 Category: Drugs & Pharmacology Authors: N Ferri A Corsini R Pontremoli Source Type: research
